Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Boron phosphate nanoparticle drug** is a preclinical boron carrier being developed by Neuboron Therapy System for boron neutron capture therapy in solid tumors as an expanded BNCT indication beyond currently established settings such as head and neck cancer and glioma. The agent is described as a nanoparticle formulation loaded with boron phosphate and designed to improve boron-10 delivery to tumor tissue through nanoparticle-mediated accumulation and intratumoral distribution. After boron delivery, therapeutic activity is intended to occur during neutron irradiation, where boron-10 captures neutrons and generates highly localized high-linear-energy-transfer radiation that selectively destroys tumor cells. This program appears to be part of Neuboron's next-generation BNCT drug portfolio and remains at the preclinical stage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on boron phosphate nanoparticle drug.